Advancing Oligonucleotide Therapeutics through Bioanalysis
Global bioanalytical support for oligonucleotide therapeutic drug development.
Expert bioanalysis for
Oligonucleotide Therapeutics
Technology-aligned bioanalytical solutions for all types of oligonucleotides, proteins, and formulations.
Our Expertise
- Decades of experience across modalities
- Specialized in nuanced bioanalysis of:
- Antisense oligonucleotides (ASOs)
- Small interfering RNA (siRNA)
- Messenger RNA (mRNA)
- Antibody Oligo conjugates (AOC)
- Aptamers, proteins, and more
- Understanding effects of chemical modifications and sequence structure on bioanalysis and overcoming assay challenges
- Expertise across matrices including blood, serum, plasma, urine, CSF, tissues
- PK/TK, PD including RISC Loading, ADA, and ADME
Your partner
- Consultative approach with personalized support and dedicated teams and instrumentation for your studies
- Fit-for-purpose assay development depending on stage of development and compliance requirements
- Instrument platform agnostic ensuring study needs are met:
LC-MS/MS, LC-HRAM, LC-FL, MSD, PCR, and LBA - Collaboration to understand modality and formulation, study requirements and endpoints
- Trusted globally by leading biopharma companies
- Extensive regulatory compliance experience with FDA, EMA, ICH (M10), NMPA and NATA
Oligonucleotides and Proteins
There are various types of oligonucleotide therapeutic modalities, including antisense oligonucleotides, siRNA, miRNA.
Oligonucleotide therapeutics are short, synthetic strands of nucleic acids designed to modulate gene expression or protein synthesis. Bioanalysis plays a critical role in characterizing their pharmacokinetics, metabolism, and tissue distribution to support safety and efficacy in drug development.
